Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC 0/0559 eye drops for neurotrophic keratitis
2019-002475-34Phase 2Completed
- Sponsor
- Recordati Rare Diseases
- Start
- Dec 2019
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of udonitrectag in neurotrophic keratitis (NK) (3 arms), sponsored by Recordati Rare Diseases. Primary endpoint: Complete corneal healing at Week 8. Started Dec 2019; status: completed.
02
Drugs
udonitrectag
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on 2019-002475-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002475-34.